Surat, Feb 10 (NationPress) The pharmaceutical sector in India has expressed enthusiasm over the recent interim trade agreement framework established between India and the United States, which provides tariff reductions on medications and various other Indian exports.

Ketan Zota, the chairman of Zota Healthcare and Dawa India, remarked that the Indian pharmaceutical industry maintained its confidence throughout the discussions, considering its vital role in the global medicine supply chain.

“Due to the lower labor costs prevalent in India, the production of pharmaceuticals is more economical, which is beneficial for the U.S.,” he stated in an interview with IANS.

He pointed out India’s significant export capabilities, mentioning, “India houses the largest U.S. Food and Drug Administration-approved manufacturing facility outside the U.S., exporting considerable amounts of generic, life-saving, and chronic disease medications, including those for diabetes, thyroid issues, and hypertension.”

Characterizing India’s achievement in the trade deal as a “significant victory,” Zota highlighted that the United States had never previously shown flexibility regarding tariffs.

“Prime Minister Narendra Modi effectively negotiated favorable conditions through proper channels. The volume of exported medicines from India is attributable to lower labor costs, resulting in reduced prices for the U.S.,” he added.

The interim framework, unveiled earlier this month, aims to recalibrate tariffs and establish clearer trade regulations between the two nations.

Under this agreement, the United States has pledged to lower tariffs on Indian exports, which encompass pharmaceuticals, textiles, gems, and aircraft parts, with certain categories potentially achieving duty-free status upon full implementation.

The framework also intends to tackle non-tariff barriers and enhance regulatory collaboration, providing greater certainty for exporters and fostering long-term trade relationships.

Zota also mentioned the expected trade agreement between India and the European Union, describing it as “immensely advantageous” for Indian pharmaceutical exporters.

“Export duties have been reduced to zero percent, and there is an expectation of increased cooperation in technology, business, and trade,” he noted.

“Pharmaceuticals will be manufactured in India, leveraging lower labor costs, which benefits both producers and global consumers,” he highlighted.

India continues to be the foremost supplier of generic medications to the United States, with the pharmaceutical sector remaining a focal point of the country's international trade profile.

The interim trade agreement is anticipated to bolster India's standing in the global pharmaceutical arena while providing enhanced clarity and stability for future exports.